R. Cervera, M. Khamashta, G. Hughes, R. Cervera, A. Tincani et al., The Euro-­-lupus project: epidemiology of systemic lupus erythematosus in Europe, vol.18, pp.869-74, 2009.

B. H. Hahn, M. Mcmahon, A. Wilkinson, W. D. Wallace, D. I. Daikh et al.,

, American College of Rheumatology Guidelines for Screening, Case Definition, Treatment and Management of Lupus Nephritis, Arthritis Care Res, vol.64, issue.6, pp.797-808, 2012.

C. C. Mok, R. Kwok, and P. Yip, Effect of Renal Disease on the Standardized Mortality Ratio and Life Expectancy of Patients With Systemic Lupus Erythematosus. Arthritis & Rheumatism, vol.65

L. M. Ortega, D. R. Schultz, O. Lenz, V. Pardo, and G. N. Contreras, Review: Lupus nephritis: pathologic features, epidemiology and a guide to therapeutic decisions, Lupus. avr, vol.19, issue.5, pp.557-74, 2010.

H. Lupique, , p.12

G. Contreras, O. Lenz, V. Pardo, E. Borja, C. Cely et al., Outcomes in African Americans and Hispanics with lupus nephritis, Kidney International, vol.69, issue.10, pp.1846-51, 2006.

Y. E. Chen, S. M. Korbet, R. S. Katz, M. M. Schwartz, and E. J. Lewis, Value of a Complete or Partial Remission in Severe Lupus Nephritis, Clin J Am Soc Nephrol, 2008.

D. J. Park, J. H. Kang, J. W. Lee, K. E. Lee, T. J. Kim et al., Risk factors to predict the development of chronic kidney disease in patients with lupus nephritis. Lupus, vol.26, pp.1139-1187, 2017.

C. C. Mok, K. Y. Ying, S. Tang, C. Y. Leung, K. W. Lee et al., Predictors and outcome of renal flares after successful cyclophosphamide treatment for diffuse proliferative lupus glomerulonephritis. Arthritis & Rheumatism, vol.50, pp.2559-68

F. A. Houssiau, C. Vasconcelos, D. Cruz, D. Sebastiani, G. D. De-ramon-garrido et al., Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis: Lessons from long-­-term followup of patients in the Euro-­-Lupus Nephritis Trial: Early Response to Treatment Predicts Good Outcome in Lupus Nephritis. Arthritis & Rheumatism [Internet]. déc, vol.50, pp.3934-3974, 2004.

M. Dall'era, M. G. Cisternas, D. E. Smilek, L. Straub, F. A. Houssiau et al., Predictors of Long-­-Term Renal Outcome in Lupus Nephritis Trials: Lessons Learned from the Euro-­-Lupus Nephritis Cohort. Arthritis & Rheumatology, vol.67, pp.1305-1318

F. Tamirou, B. R. Lauwerys, M. Dall'era, M. Mackay, B. Rovin et al., A proteinuria cut-­-off level of 0.7 g/day after 12 months of treatment best predicts long-­term renal outcome in lupus nephritis: data from the MAINTAIN Nephritis Trial, Lupus Science & Medicine, vol.2, issue.12, pp.123-000123, 2015.

M. Petri, A. Orbai, G. S. Alarcón, C. Gordon, J. T. Merrill et al., Derivation and Validation of Systemic Lupus International Collaborating Clinics Classification Criteria for Systemic Lupus Erythematosus, Revue Médicale Suisse, vol.64, pp.2677-86, 2012.

F. A. Houssiau, C. Vasconcelos, D. Cruz, D. Sebastiani, G. D. Garrido-e-de et al., Immunosuppressive therapy in lupus nephritis: The Euro-­-Lupus Nephritis Trial, a randomized trial of low-­-dose versus high-­-dose intravenous cyclophosphamide. Arthritis & Rheumatism, vol.46, pp.2121-2152

N. Maroz, M. S. Segal, E. Lupus-nephritis, G. K. Bertsias, M. Tektonidou et al., Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-­-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Annals of the Rheumatic Diseases, The American Journal of the Medical Sciences, vol.346, pp.1771-82, 2012.

S. M. Korbet and E. J. Lewis, Severe lupus nephritis: the predictive value of a ? 50% reduction in proteinuria at 6 months, Nephrol Dial Transplant. sept, vol.28, issue.9, pp.2313-2321, 2013.

H. M. Bastian, J. M. Roseman, G. Mcgwin, G. S. Alarcón, A. W. Friedman et al., Systemic lupus erythematosus in three ethnic groups. XII. Risk factors for lupus nephritis after diagnosis, Lupus, vol.11, issue.3, pp.152-60, 2002.

G. Contreras, V. Pardo, C. Cely, E. Borja, A. Hurtado et al., Factors associated with poor outcomes in patients with lupus nephritis, Lupus, vol.14, issue.11, pp.890-895, 2005.

S. M. Korbet, E. J. Lewis, M. M. Schwartz, M. Reichlin, J. Evans et al., Factors predictive of outcome in severe lupus nephritis, American Journal of Kidney Diseases, vol.35, issue.5, pp.904-918, 2000.

R. G. Barr, Prognosis in proliferative lupus nephritis: the role of socio-­-economic status and race/ethnicity. Nephrology Dialysis Transplantation, vol.18, pp.2039-2085, 2003.

N. Gensous, A. Marti, T. Barnetche, P. Blanco, L. E. Seneschal et al., Predictive biological markers of systemic lupus erythematosus flares: a systematic literature review, Arthritis Res Ther, vol.19, issue.1, p.238, 2017.

T. M. Chan, K. C. Tse, C. S. Tang, K. N. Lai, and F. K. Li, Long-­-term outcome of patients with diffuse proliferative lupus nephritis treated with prednisolone and oral cyclophosphamide followed by azathioprine, Lupus, vol.14, issue.4, pp.265-72, 2005.

G. G. Illei, K. Takada, D. Parkin, H. A. Austin, M. Crane et al., Renal flares are common in patients with severe proliferative lupus nephritis treated with pulse immunosuppressive therapy: long-­-term followup of a cohort of 145 patients participating in randomized controlled studies, Arthritis Rheum. avr, vol.46, issue.4, pp.995-1002, 2002.

J. T. Gustafsson, H. Lindberg, M. Gunnarsson, I. Pettersson, S. Elvin et al., Excess atherosclerosis in systemic lupus erythematosus,-­-A matter of renal involvement: Case control study of 281 SLE patients and 281 individually matched population controls, PLoS ONE, vol.12, issue.4, p.174572, 2017.

G. Moroni, D. Ventura, P. Riva, P. Panzeri, S. Quaglini et al., Antiphospholipid antibodies are associated with an increased risk for chronic renal insufficiency in patients with lupus nephritis, Am J Kidney Dis. janv, vol.43, issue.1, pp.28-36, 2004.

V. I. Bibliographie,

E. Masson, La néphropathie lupique : le point en, 2014.

E. ,

. Disponible,

R. Tomioka, K. Tani, K. Sato, C. Suzuka, Y. Toyoda et al., Observations on the occurrence of exacerbations in clinical course of systemic lupus erythematosus. The Journal of Medical Investigation, vol.55, pp.112-121, 2008.

G. K. Bertsias, M. Tektonidou, Z. Amoura, M. Aringer, I. Bajema et al., Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Annals of the Rheumatic Diseases, vol.71, pp.1771-82, 2012.

B. H. Hahn, M. Mcmahon, A. Wilkinson, W. D. Wallace, D. I. Daikh et al., American College of Rheumatology Guidelines for Screening, Case Definition, Treatment and Management of Lupus Nephritis, Arthritis Care Res, vol.64, issue.6, pp.797-808

C. C. Mok, K. Y. Ying, S. Tang, C. Y. Leung, K. W. Lee et al., Predictors and outcome of renal flares after successful cyclophosphamide treatment for diffuse proliferative lupus glomerulonephritis. Arthritis & Rheumatism, vol.50, pp.2559-68

R. Cervera, M. Khamashta, G. Hughes, R. Cervera, A. Tincani et al., The Euro-lupus project: epidemiology of systemic lupus erythematosus in Europe, vol.18, pp.869-74, 2009.

G. S. Alarcón and G. Mcgwin, Baseline characteristics of a multiethnic lupus cohort: PROFILE

F. Wang, C. L. Wang, C. T. Tan, and M. Manivasagar, Systemic lupus erythematosus in Malaysia: a study of 539 patients and comparison of prevalence and disease expression in different racial and gender groups, Lupus, vol.6, issue.3, pp.248-53, 1997.

H. M. Bastian, J. M. Roseman, G. Mcgwin, G. S. Alarcón, A. W. Friedman et al., Systemic lupus erythematosus in three ethnic groups. XII. Risk factors for lupus nephritis after diagnosis, Lupus, vol.11, issue.3, pp.152-60

L. M. Ortega, D. R. Schultz, O. Lenz, V. Pardo, and G. N. Contreras, Review: Lupus nephritis: pathologic features, epidemiology and a guide to therapeutic decisions, Lupus. avr, vol.19, issue.5, pp.557-74, 2010.

V. A. Seligman, R. F. Lum, J. L. Olson, H. Li, and L. A. Criswell, Demographic differences in the development of lupus nephritis: a retrospective analysis, The American Journal of Medicine

F. A. Houssiau, C. Vasconcelos, D. Cruz, D. Sebastiani, G. D. De-ramon-garrido et al.,

J. Cortés-hernández, J. Ordi-ros, M. Labrador, S. Buján, E. Balada et al., Antihistone and anti-double-stranded deoxyribonucleic acid antibodies are associated with renal disease in systemic lupus erythematosus, Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis: Lessons from long-term followup of patients in the Euro-Lupus Nephritis Trial: Early Response to Treatment Predicts Good Outcome in Lupus Nephritis. Arthritis & Rheumatism [Internet]. déc, vol.50, pp.165-73, 2004.

J. Kabeerdoss, N. Gupta, S. Pulukool, H. Mohan, G. Mahasampath et al., Anti-C1q Antibody is Associated with Renal and Cutaneous Manifestations in Asian Indian Patients with Systemic Lupus Erythematosus, J Clin Diagn Res. mars, vol.11, issue.3, pp.39-42, 2017.

C. A. Peschken and J. M. Esdaile, Systemic lupus erythematosus in North American Indians: a population based study, J Rheumatol. août, vol.27, issue.8, pp.1884-91, 2000.

C. C. Mok, R. Kwok, and P. Yip, Effect of Renal Disease on the Standardized Mortality Ratio and Life Expectancy of Patients With Systemic Lupus Erythematosus. Arthritis & Rheumatism, vol.65, pp.2154-60

R. Cervera, M. A. Khamashta, J. Font, G. D. Sebastiani, A. Gil et al., Morbidity and Mortality in Systemic Lupus Erythematosus During a 10-Year Period: A Comparison of Early and Late Manifestations in a Cohort of 1,000 Patients, vol.82, p.299, 2003.

N. Kasitanon, L. S. Magder, M. Petri, S. M. Korbet, E. J. Lewis et al., Factors predictive of outcome in severe lupus nephritis. Lupus Nephritis Collaborative Study Group, Am J Kidney Dis. mai, vol.85, issue.3, pp.904-918, 2000.

Y. E. Chen, S. M. Korbet, R. S. Katz, M. M. Schwartz, and E. J. Lewis, Value of a Complete or Partial Remission in Severe Lupus Nephritis, Clin J Am Soc Nephrol, 2008.

S. R. Schoenfeld, S. Kasturi, and K. H. Costenbader, The epidemiology of atherosclerotic cardiovascular disease among patients with SLE: A systematic review. Seminars in Arthritis and Rheumatism, vol.3, pp.77-95

J. T. Gustafsson, H. Lindberg, M. Gunnarsson, I. Pettersson, S. Elvin et al., Excess atherosclerosis in systemic lupus erythematosus,-A matter of renal involvement: Case control study of 281 SLE patients and 281 individually matched population controls, PLoS ONE, vol.12, issue.4, p.174572, 2017.

M. Mcmahon, B. H. Hahn, B. Skaggs, and . Lupique, Systemic lupus erythematosus and cardiovascular disease: prediction and potential for therapeutic intervention, vol.7, p.12, 2018.

J. Ioannidis, K. A. Boki, M. E. Katsorida, A. A. Drosos, F. N. Skopouli et al.,

, Remission, relapse, and re-remission of proliferative lupus nephritis treated with cyclophosphamide, Kidney International, vol.57, issue.1, pp.258-64, 2000.

G. S. Hill, M. Delahousse, D. Nochy, É. Thervet, F. Vrtovsnik et al., Outcome of relapse in lupus nephritis: Roles of reversal of renal fibrosis and response of inflammation to therapy, Kidney International, vol.61, issue.6, pp.2176-86, 2002.

M. El-hachmi, M. Jadoul, C. Lefebvre, G. Depresseux, and F. A. Houssiau, Relapses of lupus nephritis: incidence, risk factors, serology and impact on outcome, vol.12, pp.692-698, 2003.

F. Tamirou, D. Cruz, D. Sangle, S. Remy, P. Vasconcelos et al., Long-term follow-up of the MAINTAIN Nephritis Trial, comparing azathioprine and mycophenolate mofetil as maintenance therapy of lupus nephritis, Ann Rheum Dis. mars, vol.75, issue.3, pp.526-557, 2016.

J. J. Weening, D. Agati, V. D. Schwartz, M. M. Seshan, S. V. Alpers et al., The Classification of Glomerulonephritis in Systemic Lupus Erythematosus Revisited, vol.2, pp.241-50

C. M. Haring, A. Rietveld, J. Van-den-brand, and J. Berden, Segmental and Global Subclasses of Class IV Lupus Nephritis Have Similar Renal Outcomes, Journal of the American Society of Nephrology, vol.23, issue.1, pp.149-54

M. M. Schwartz, S. M. Korbet, and E. J. Lewis, The prognosis and pathogenesis of severe lupus glomerulonephritis, Nephrology Dialysis Transplantation, vol.23, issue.4, pp.1298-306, 2008.

F. Yu, L. Wu, Y. Tan, L. Li, C. Wang et al., Tubulointerstitial lesions of patients with lupus nephritis classified by the 2003 International Society of Nephrology and Renal Pathology Society system, Kidney International, vol.77, pp.820-829

L. Wu, Y. F. Tan, Y. Qu, Z. Chen, M. Wang et al., Inclusion of renal vascular lesions in the 2003 ISN/RPS system for classifying lupus nephritis improves renal outcome predictions, Kidney International, vol.83, issue.4, pp.715-738, 2013.

T. Kofman, C. Narjoz, Q. Raimbourg, M. Loriot, A. Karras et al., Collapsing glomerulopathy associated lupus in a black female with homozygous APOL1 mutation, Lupus, vol.21, issue.1, pp.1459-62, 2012.

C. P. Larsen, M. L. Beggs, M. Saeed, and P. D. Walker, Apolipoprotein L1 Risk Variants Associate with Systemic Lupus Erythematosus-Associated Collapsing Glomerulopathy, Journal of the American Society of Nephrology [Internet]. 1 mai, vol.24, issue.5, pp.722-727, 2013.

M. Petri, A. Orbai, G. S. Alarcón, C. Gordon, J. T. Merrill et al., Derivation and Validation of Systemic Lupus International Collaborating Clinics Classification Criteria for Systemic Lupus Erythematosus, Arthritis Research & Therapy, vol.64, issue.8, p.202, 2012.

J. Mikdashi and O. Nived, Measuring disease activity in adults with systemic lupus erythematosus: the challenges of administrative burden and responsiveness to patient concerns in clinical research, Arthritis Res Ther, vol.17, issue.1, pp.487-90, 2015.

H. Ding, M. Kharboutli, R. Saxena, and T. Wu, Insulin-like growth factor binding protein-2 as a novel biomarker for disease activity and renal pathology changes in lupus nephritis, Clin Exp Immunol. avr, vol.184, issue.1, pp.11-19, 2016.

T. Urrego, B. Ortiz-reyes, A. L. Vanegas-garcía, C. H. Muñoz, L. A. González et al., Utility of urinary transferrin and ceruloplasmin in patients with systemic lupus erythematosus for differentiating patients with lupus nephritis, Reumatol Clin. 9 mars, 2018.

H. A. Austin, J. H. Klippel, J. E. Balow, N. G. Le-riche, A. D. Steinberg et al., Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs, N Engl J Med. 6 mars, vol.314, issue.10, pp.614-623, 1986.

A. D. Steinberg and S. C. Steinberg, Long-term preservation of renal function in patients with lupus nephritis receiving treatment that includes cyclophosphamide versus those treated with prednisone only, Arthritis Rheum. août, vol.34, issue.8, pp.945-50, 1991.

M. F. Gourley, H. A. Austin, D. Scott, C. H. Yarboro, E. M. Vaughan et al.,

, Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis. A randomized, controlled trial, Ann Intern Med, vol.125, issue.7, pp.549-57, 1996.

V. K. Bansal and J. A. Beto, Treatment of lupus nephritis: a meta-analysis of clinical trials, Am J Kidney Dis. févr, vol.29, issue.2, pp.193-202, 1997.

R. S. Flanc, M. A. Roberts, G. Strippoli, S. J. Chadban, P. G. Kerr et al., Treatment of diffuse proliferative lupus nephritis: a meta-analysis of randomized controlled trials, Am J Kidney Dis. févr, vol.43, issue.2, pp.197-208, 2004.

F. A. Houssiau, C. Vasconcelos, D. Cruz, D. Sebastiani, G. D. Garrido-e-de et al.,

, Immunosuppressive therapy in lupus nephritis: The Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis & Rheumatism, p.14

, , vol.46, pp.2121-2152, 2018.

W. Hu, Z. Liu, H. Chen, Z. Tang, Q. Wang et al., Mycophenolate mofetil vs cyclophosphamide therapy for patients with diffuse proliferative lupus nephritis, Chin Med J. mai, vol.115, issue.5, pp.705-714, 2002.

T. M. Chan, F. K. Li, C. S. Tang, R. W. Wong, G. X. Fang et al., Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group, N Engl J Med, vol.343, issue.16, pp.1156-62, 2000.

E. M. Ginzler, M. A. Dooley, C. Aranow, M. Y. Kim, J. Buyon et al., Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis, N Engl J Med, vol.353, issue.21, pp.2219-2247, 2005.

T. Chan, K. Tse, C. Tang, M. Mok, F. Li et al., Long-Term Study of Mycophenolate Mofetil as Continuous Induction and Maintenance Treatment for Diffuse Proliferative Lupus Nephritis, vol.4, pp.1076-84

G. B. Appel, G. Contreras, M. A. Dooley, E. M. Ginzler, D. Isenberg et al., Mycophenolate Mofetil versus Cyclophosphamide for Induction Treatment of Lupus Nephritis, Journal of the American Society of Nephrology, vol.20, issue.1, pp.1103-1115, 2009.

L. M. Ong, L. S. Hooi, T. O. Lim, B. L. Goh, G. Ahmad et al., Randomized controlled trial of pulse intravenous cyclophosphamide versus mycophenolate mofetil in the induction therapy of proliferative lupus nephritis, Nephrology, vol.10, issue.5, pp.504-514

C. Gabriel, P. Victoriano, L. Baudouin, L. Oliver, E. T. Patricia et al., Sequential Therapies for Proliferative Lupus Nephritis, The New England Journal of Medicine, vol.10, 2004.

M. A. Dooley, J. D. Ginzler, E. M. Isenberg, D. Olsen, N. J. Wofsy et al., Mycophenolate versus Azathioprine as Maintenance Therapy for Lupus Nephritis, New England Journal of Medicine, vol.365, issue.17, pp.1886-95, 1920.

F. A. Houssiau, D. Cruz, D. Sangle, S. Remy, P. Vasconcelos et al., Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: results from the MAINTAIN Nephritis Trial. Annals of the Rheumatic Diseases, vol.69, pp.2083-2092, 2010.

G. P. Fra, G. C. Avanzi, and E. Bartoli, Remission of refractory lupus nephritis with a protocol including rituximab, Lupus, vol.12, issue.10, pp.783-790, 2003.

R. F. Van-vollenhoven, I. Gunnarsson, E. Welin-henriksson, B. Sundelin, A. Osterborg et al., Biopsy-verified response of severe lupus nephritis to treatment with rituximab (anti-CD20 monoclonal antibody) plus cyclophosphamide after biopsy-documented failure to respond to cyclophosphamide alone, Scand J Rheumatol, vol.33, issue.6, pp.423-430, 2004.

H. Ogawa, H. Kameda, H. Nagasawa, N. Sekiguchi, H. Takei et al., Prospective study of low-dose cyclosporine A in patients with refractory lupus nephritis, Mod Rheumatol, vol.17, issue.2, pp.92-99, 2007.

G. Moroni, A Randomized Pilot Trial Comparing Cyclosporine and Azathioprine for

, Maintenance Therapy in Diffuse Lupus Nephritis over Four Years, Clinical Journal of the American Society of Nephrology, vol.1, issue.12, pp.925-957, 2006.

W. Chen, X. Tang, Q. Liu, W. Chen, P. Fu et al., Short-term outcomes of induction therapy with tacrolimus versus cyclophosphamide for active lupus nephritis: A multicenter randomized clinical trial, Am J Kidney Dis. févr, vol.57, issue.2, pp.235-279, 2011.

Z. Liu, H. Zhang, Z. Liu, C. Xing, P. Fu et al., Multitarget therapy for induction treatment of lupus nephritis: a randomized trial, Ann Intern Med. 6 janv, vol.162, issue.1, pp.18-26, 2015.

C. M. Lanata, T. Mahmood, D. M. Fine, and M. Petri, Combination therapy of mycophenolate mofetil and tacrolimus in lupus nephritis, Lupus. juill, vol.19, issue.8, pp.935-975, 2010.

J. Cortés-hernández, M. T. Torres-salido, A. S. Medrano, M. V. Tarrés, and J. Ordi-ros, Long-term outcomes-mycophenolate mofetil treatment for lupus nephritis with addition of tacrolimus for resistant cases, Nephrol Dial Transplant. déc, vol.25, issue.12, pp.3939-3987, 2010.

H. H. Euler, J. O. Schroeder, R. A. Zeuner, and E. Teske, A randomized trial of plasmapheresis and subsequent pulse cyclophosphamide in severe lupus: design of the LPSG trial, Int J Artif Organs, vol.14, issue.10, pp.639-685, 1991.

E. J. Lewis, L. G. Hunsicker, S. P. Lan, R. D. Rohde, and J. M. Lachin, A controlled trial of plasmapheresis therapy in severe lupus nephritis. The Lupus Nephritis Collaborative Study Group, N Engl J Med. 21 mai, vol.326, issue.21, pp.1373-1382, 1992.

B. H. Rovin, R. Furie, K. Latinis, R. J. Looney, F. C. Fervenza et al., Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: The lupus nephritis assessment with rituximab study. Arthritis & Rheumatism

, The ACCESS Trial Group, Treatment of Lupus Nephritis With Abatacept: The Abatacept and Cyclophosphamide Combination Efficacy and Safety Study: Abatacept in Lupus Nephritis. Arthritis & Rheumatology, vol.64, pp.3096-104, 2014.

R. Furie, K. Nicholls, T. Cheng, F. Houssiau, -. Burgos et al., Efficacy and Safety of Abatacept in Lupus Nephritis: A Twelve-Month

. Arthritis-&-rheumatology, , vol.66, pp.379-89

R. Pepper, M. Griffith, C. Kirwan, J. Levy, D. Taube et al., Rituximab is an effective treatment for lupus nephritis and allows a reduction in maintenance steroids, Nephrology Dialysis Transplantation, vol.24, issue.12, pp.3717-3740, 2009.

M. B. Condon, D. Ashby, R. J. Pepper, H. T. Cook, J. B. Levy et al., Prospective observational single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroids. Annals of the Rheumatic Diseases, vol.72, pp.1280-1286

H. A. Austin, D. T. Boumpas, E. M. Vaughan, and J. E. Balow, High-risk features of lupus nephritis: importance of race and clinical and histological factors in 166 patients, Nephrol Dial Transplant, vol.10, issue.9, pp.1620-1628, 1995.

M. A. Dooley, S. Hogan, C. Jennette, and R. Falk, Cyclophosphamide therapy for lupus nephritis: poor renal survival in black Americans. Glomerular Disease Collaborative Network, Kidney Int. avr, vol.51, issue.4, pp.1188-95, 1997.

G. Contreras, O. Lenz, V. Pardo, E. Borja, C. Cely et al., Outcomes in African Americans and Hispanics with lupus nephritis, Kidney International, vol.69, issue.10, pp.1846-51, 2006.

R. G. Barr, Prognosis in proliferative lupus nephritis: the role of socio-economic status and race/ethnicity, Nephrology Dialysis Transplantation, vol.18, issue.1, pp.2039-2085, 2003.

G. Contreras, V. Pardo, C. Cely, E. Borja, A. Hurtado et al., Factors associated with poor outcomes in patients with lupus nephritis, Lupus, vol.14, issue.11, pp.890-895, 2005.

J. Cortés-herández, J. Ordi-ros, M. Labrador, A. Segarra, J. L. Tovar et al., Predictors of poor renal outcome in patients with lupus nephritis treated with combined pulses of cyclophosphamide and methylprednisolone, Lupus, 2003.

, , vol.12, pp.287-96

G. B. Appel, D. J. Cohen, C. L. Pirani, J. I. Meltzer, and D. Estes, Long-term follow-up of patients with lupus nephritis. A study based on the classification of the World Health Organization, Am J Med. nov, vol.83, issue.5, pp.877-85, 1987.

D. J. Park, J. H. Kang, J. W. Lee, K. E. Lee, T. J. Kim et al., Risk factors to predict the development of chronic kidney disease in patients with lupus nephritis, Lupus, vol.26, issue.11, pp.1139-1187, 2017.

G. Moroni, D. Ventura, P. Riva, P. Panzeri, S. Quaglini et al., Antiphospholipid antibodies are associated with an increased risk for chronic renal insufficiency in patients with lupus nephritis, Am J Kidney Dis. janv, vol.43, issue.1, pp.28-36, 2004.

N. Gensous, A. Marti, T. Barnetche, P. Blanco, L. E. Seneschal et al., Predictive biological markers of systemic lupus erythematosus flares: a systematic literature review, Arthritis Res Ther, vol.19, issue.1, p.238, 2017.

R. S. Laitman, D. Gucklich, L. B. Sablay, A. I. Grayzel, P. Barland et al., Effect of long-term normalization of serum complement levels on the course of lupus nephritis, The American Journal of Medicine, vol.87, issue.2, p.80687

L. Mercadal, S. T. Montcel, . Du, D. Nochy, G. Queffeulou et al., Factors affecting outcome and prognosis in membranous lupus nephropathy, Nephrol Dial Transplant, vol.17, issue.1, pp.1771-1779, 2002.

P. C. Wilson, M. Kashgarian, and G. Moeckel, Interstitial inflammation and interstitial fibrosis and tubular atrophy predict renal survival in lupus nephritis, Clinical Kidney Journal [Internet]. 1 avr, vol.11, issue.2, pp.207-225, 2018.

B. Obri?c?, R. Jurubi??, A. Andronesi, B. Sorohan, C. Achim et al., Histological predictors of renal outcome in lupus nephritis: the importance of tubulointerstitial lesions and scoring of glomerular lesions, Lupus. août, vol.27, issue.9, pp.1455-63, 2018.

H. Ikeuchi, K. Hiromura, K. Kayakabe, K. A. Tshilela, K. Uchiyama et al., Renal outcomes in mixed proliferative and membranous lupus nephritis (Class III/IV + V): A long-term observational study, Mod Rheumatol, vol.26, issue.6, pp.908-921, 2016.

G. S. Hill, M. Delahousse, D. Nochy, and J. Bariéty, Class IV-S versus class IV-G lupus nephritis: clinical and morphologic differences suggesting different pathogenesis. Kidney Int, vol.68, pp.2288-97, 2005.

I. M. Bajema, S. Wilhelmus, C. E. Alpers, J. A. Bruijn, R. B. Colvin et al., Revision of the International Society of Nephrology/Renal Pathology Society classification for lupus nephritis: clarification of definitions, and modified National Institutes of Health activity and chronicity indices, Kidney International, vol.93, issue.4, p.30859

F. Yu, Y. Tan, G. Liu, S. Wang, W. Zou et al., Clinicopathological characteristics and outcomes of patients with crescentic lupus nephritis, Kidney Int. août, vol.76, issue.3, pp.307-324, 2009.

A. Pakozdi, D. Pyne, M. Sheaff, and R. Rajakariar, Utility of a repeat renal biopsy in lupus nephritis: a single centre experience, Nephrol Dial Transplant. 1 mars, vol.33, issue.3, pp.507-520, 2018.

M. R. Clark, K. Trotter, and A. Chang, The Pathogenesis and Therapeutic Implications of

, Tubulointerstitial Inflammation in Human Lupus Nephritis. Semin Nephrol. sept, vol.35, issue.5, pp.455-64, 2015.

L. Couzi, P. Merville, C. Deminière, J. Moreau, C. Combe et al., Predominance of CD8+ T lymphocytes among periglomerular infiltrating cells and link to the prognosis of class III and class IV lupus nephritis, Arthritis Rheum. juill, vol.56, issue.7, pp.2362-70, 2007.

G. S. Hill, M. Delahousse, D. Nochy, P. Rémy, M. F. Méry et al., Predictive power of the second renal biopsy in lupus nephritis: Significance of macrophages, Kidney International

S. M. Korbet and E. J. Lewis, Severe lupus nephritis: the predictive value of a ? 50% reduction in proteinuria at 6 months, Nephrol Dial Transplant. sept, vol.28, issue.9, pp.2313-2321, 2013.

M. Dall'era, M. G. Cisternas, D. E. Smilek, L. Straub, F. A. Houssiau et al., Predictors of Long-Term Renal Outcome in Lupus Nephritis Trials: Lessons Learned from the Euro-Lupus Nephritis Cohort. Arthritis & Rheumatology, vol.67, pp.1305-1318

F. Tamirou, B. R. Lauwerys, M. Dall'era, M. Mackay, B. Rovin et al., A proteinuria cut-off level of 0.7 g/day after 12 months of treatment best predicts long-term renal outcome in lupus nephritis: data from the MAINTAIN Nephritis Trial, Lupus Science & Medicine, vol.2, issue.12, pp.123-000123, 2015.

B. Bose, E. D. Silverman, and J. M. Bargman, Ten Common Mistakes in the Management of Lupus Nephritis, American Journal of Kidney Diseases, vol.63, issue.4, pp.667-76, 2014.

M. Dall'era, D. Stone, V. Levesque, M. Cisternas, and D. Wofsy, Identification of biomarkers that predict response to treatment of lupus nephritis with mycophenolate mofetil or pulse cyclophosphamide. Arthritis Care & Research [Internet]. 1 mars, vol.63, pp.351-358, 2011.

D. Wofsy, J. L. Hillson, and B. Diamond, Comparison of Alternative Primary Outcome Measures for Use in Lupus Nephritis Clinical Trials: Outcome Measures for Lupus Nephritis. Arthritis & Rheumatism, vol.65, pp.1586-91

G. G. Illei, K. Takada, D. Parkin, H. A. Austin, M. Crane et al., Renal flares are common in patients with severe proliferative lupus nephritis treated with pulse immunosuppressive therapy: long-term followup of a cohort of 145 patients participating in randomized controlled studies, Arthritis Rheum. avr, vol.46, issue.4, pp.995-1002, 2002.

T. M. Chan, K. C. Tse, C. S. Tang, K. N. Lai, and F. K. Li, Long-term outcome of patients with diffuse proliferative lupus nephritis treated with prednisolone and oral cyclophosphamide followed by azathioprine, Lupus, vol.14, issue.4, pp.265-72, 2005.

M. Hajji, A. Harzallah, H. Kaaroud, S. Barbouch, F. B. Hamida et al., Factors associated with relapse of lupus nephritis: A single center study of 249 cases, Saudi J Kidney Dis Transpl. déc, vol.28, issue.6, pp.1349-55, 2017.

N. Costedoat-­-chalumeau, Z. Amoura, J. Hulot, H. A. Hammoud, G. Aymard et al., Low blood concentration of hydroxychloroquine is a marker for and predictor of disease exacerbations in patients with systemic lupus erythematosus. Arthritis & Rheumatism, vol.54, pp.3284-90

N. Costedoat-chalumeau, Z. Amoura, J. Hulot, G. Aymard, G. Leroux et al., Very low blood hydroxychloroquine concentration as an objective marker of poor adherence to treatment of systemic lupus erythematosus. Annals of the Rheumatic Diseases, vol.12, pp.821-825